Skip to main content

tumor suppressor Archives

Discovery offers insight for development of cancer therapies targeting mutant p53

Sep. 2, 2021—Vanderbilt researchers have discovered that aneuploidy (an abnormal number of chromosomes) drives malignant phenotypes in cells expressing mutant p53, a tumor suppressor protein that is mutated in more than half of all human cancers.

Read more


New markers of colorectal cancer risk

Oct. 29, 2020—Vanderbilt epidemiologists identified new markers for colorectal cancer risk and characterized a previously unidentified tumor suppressor that regulates overall tumor volume in vivo.

Read more


COX-2 ‘conjugate’ may slow growth of some tumors: study

Jan. 19, 2017—More than a decade after the anti-inflammatory drugs Vioxx and Bextra were pulled from the market because of a heightened risk of heart attack and stroke in some patients, COX-2 inhibitors may be on the verge of a comeback, this time as anti-cancer agents.

Read more


Stomach bug alters tumor suppressor

Oct. 23, 2012—The stomach bug Helicobacter pylori increases forms of a protein that promote tumor development, perhaps explaining how it elevates risk for gastric cancer.

Read more


Protein repairs esophageal DNA damage

Jan. 25, 2012—A protein involved in repairing DNA damage associated with gastric reflux may play a tumor suppressor role in the esophagus and could represent a target for therapies to combat esophageal cancer.

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more